Participated · Series E · Mar 2025

Supira Medical, a Shifamed portfolio company based in Los Gatos, Calif., is developing the Supira System, an investigational next-generation pVAD intended for HRPCI and cardiogenic shock. The company recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study, enrolling 15 patients across four clinical sites, and reports the Supira System has benefited 85 HRPCI patients to date. The device is investigational and not approved for sale in the U.S. or elsewhere. Supira plans to expand its clinical programs for both HRPCI and cardiogenic shock, including the SUPPORT II U.S. Pivotal Study for HRPCI that will be used to seek FDA PMA approval. The company aims to use new capital to accelerate those clinical programs and further validate its low-profile, high-flow technology platform. Supira Medical is advancing the Supira System, a percutaneous ventricular assist device (pVAD) featuring a novel low-profile, high continuous-flow design intended to provide full hemodynamic support initially for high-risk percutaneous coronary interventions and subsequently for cardiogenic shock. The system is built with a 10F profile to minimize vascular complications and incorporates multiple sensors for real-time pressure measurements. The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S. Supira is led by President and CEO Dr. Nitin Salunke and is a portfolio company of Shifamed, LLC. The company plans to expand its currently enrolling OUS studies, plan for U.S. studies, and prepare for a U.S. pivotal study submission. It raised $40M in Series D financing to support those clinical and regulatory activities. Supira Medical is developing a next-generation percutaneous ventricular assist device (pVAD) intended to provide temporary mechanical circulatory support for high-risk patients. The device is aimed for use during interventional procedures such as stent placement or angioplasty and to treat patients suffering from cardiogenic shock following severe heart attacks. The company is led by CEO Dr. Nitin Salunke and is a Shifamed portfolio company based in Los Gatos, CA. Supira plans to finalize product development and initiate a first-in-human clinical study for its pVAD. Financially, the company recently completed a financing round to support those activities. Supira Medical is focused on developing a next-generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. The company was formed as the newest portfolio company of Shifamed and is located in Shifamed's facility in Silicon Valley. Jean Orth was appointed CEO in December 2017 and brings more than 25 years of cardiology-centric medical device experience. Supira closed a $15.5M financing that officially closed on April 25, 2018 to support its early development efforts. The round was led by The Capital Partnership with participation from Cormorant Asset Management and Shifamed Angels. Shifamed's incubator track record includes multiple exits, providing an experienced sponsor and potential exit pathways for its portfolio companies.

Participated · Series C · Mar 2025

Laplace Interventional is a Minnesota-based medical device company developing a prosthetic transcatheter tricuspid valve delivered via a minimally invasive procedure to avoid open-heart surgery. The device is intended to improve quality of life for patients with tricuspid regurgitation. The company has completed an Early Feasibility Study (EFS) experience treating three patients (all discharged home within 1–2 days) and has enrolled 22 patients in the U.S. EFS and 25 patients globally. Laplace announced a $22M Series C financing to support completion of its U.S. and OUS feasibility studies and to work toward initiating a pivotal study. The company added Ned Scheetz of Aphelion Capital to its board as part of the financing announcement. The device remains in development and is not approved or cleared by the FDA or any other regulatory body. Laplace Interventional is a Minneapolis, MN–based medical device company developing a transcatheter prosthetic valve system to treat patients with tricuspid regurgitation. The device is designed to be delivered through patient vasculature, avoiding open‑heart surgery and aiming to increase life expectancy and improve quality of life for patients with TR. The technology is in an early stage of development and is not approved or cleared by the FDA or other regulatory bodies. The company intends to use the new capital to pursue first‑in‑human (FIH) and clinical feasibility evaluations of its valve system. Ramji Iyer is founder and CEO, and the company has recently added industry executives to its board, including Jenny Barba and Todd Mortier. Laplace Interventional is a Minnesota-based medical device company developing a transcatheter tricuspid valve technology. Its core product is a prosthetic valve designed for minimally invasive delivery that avoids open-heart surgery to treat tricuspid regurgitation. The company says the device aims to increase life expectancy and improve quality of life for patients with TR. Laplace recently closed a $7.9M Series A to fund progress toward preclinical milestones. Leadership added two directors to the board, including William Dai of ShangBay Capital, a participant in the round. The device remains in early-stage development and is not approved or cleared by the FDA or other regulatory bodies.

Participated · Series B · Sep 2024

CorFlow Therapeutics is developing the CoFl system to provide timely, accurate detection of microvascular obstruction (MVO) in the cath lab immediately after stent implantation and to enable localized delivery of therapeutics to the microvasculature. The technology integrates with standard guide catheter and wire access and is intended to both diagnose MVO and deliver treatments at the point of care. CorFlow has reported recent data from over 70 patients in its first-in-human MOCA I trial and an extensive preclinical program supporting its approach. The company plans a MOCA II pivotal IDE trial in the US and Europe to validate CoFl against contrast-enhanced cardiac MRI and to support US market clearance. It will also run an adaptive platform therapy study in Europe to evaluate multiple therapeutic agents delivered via CoFl and measure clinical and imaging outcomes up to six months. Headquartered in Baar, Switzerland and founded in 2016, CorFlow is collaborating with academic partners including the University of Bern, ETH Zurich and University Hospital Zurich. CorFlow Therapeutics develops the Controlled Flow Infusion (CoFITM) system and a proprietary dynamic Microvascular Resistance (dMVRTM) concept to detect and treat microvascular obstruction (MVO) in the cathlab. The CoFITM system is positioned as a combined diagnostic and therapeutic technology that enables detection and low-flow infusion treatment of MVO immediately after reopening epicardial arteries. Seed proceeds will finance the First-in-Man MOCA I (MVO with CoFITM System Assessment) safety and feasibility trial in 40 acute heart attack patients. MOCA I will measure peri-procedural dMVR and compare those values to post-procedure contrast-enhanced MRI, and will investigate low-flow infusion of approved therapeutic agents to reduce MVO. The company cites that around 50% of acute heart attack patients develop MVO, translating to roughly 200,000 patients annually, and notes MVO is an independent predictor of heart failure and death. CorFlow has presented nonclinical data at major cardiology meetings (ACC, EuroPCR, ESC) and plans further presentation at TCT; it aims to raise a Series A in 2019 to secure longer-term R&D, clinical, and regulatory activities. CorFlow Therapeutics is developing proprietary technologies to diagnose and treat microvascular obstructions (MVO) in severe heart attack patients. Its technologies aim to enable interventional cardiologists to diagnose and treat MVO, potentially reducing short- and long-term complication rates. The company is led by CEO and co-founder Jon H. Hoem. Headquartered in Baar, Switzerland, CorFlow has raised more than CHF5M in seed funding to date. It completed a CHF 2.6M first close of a Seed+ round to advance clinical development. The company plans to use the funds to finance the 80-patient First-in-Man MOCA (MVO with CoFI™ System Assessment) clinical trial in Europe and intends the Seed+ as the basis for a larger Series A to secure long-term R&D, clinical, and regulatory activities.

Participated · Series C · Jul 2024

Adona Medical is a pre-clinical medical technology company focused on solutions for advanced heart failure. It is developing an adjustable interatrial shunt with integrated bi-atrial pressure monitoring alongside remote patient monitoring components as part of a heart failure management platform. The platform is investigational and not approved for use in the U.S. or elsewhere. The company plans to use newly raised capital to further product development and to initiate clinical use of the adjustable interatrial shunt and monitoring capabilities. Adona Medical raised $33.5M in a Series C financing to support those plans. The company is a Los Gatos, CA–based Shifamed portfolio company led by CEO Brian Fahey. Adona Medical is a pre-clinical stage medical technology company developing a next-generation heart failure management platform. The company is led by CEO Brian Fahey and is a privately held portfolio company of Shifamed LLC. Its core work focuses on next-generation solutions for patients with advanced heart failure. Adona intends to use new funding to complete product development and to support further evaluation of its platform. The article does not provide operating metrics such as revenue or user counts. Adona is based in Campbell, California. Adona Medical focuses on advanced interventional approaches for heart failure. The company is a privately held portfolio company of medical innovation hub Shifamed LLC and is based in Campbell, CA. It raised $2.5M in seed financing to advance product development and expand its intellectual property portfolio. The round was funded exclusively by select Shifamed accredited angel investors. Leadership includes newly appointed CEO Brian Fahey and Chairman Amr Salahieh. Fahey joins Adona with over 15 years of medtech leadership and product development experience.

Participated · Seed · Mar 2024

ConKay Medical Systems is developing a unique, completely adjustable annular repair catheter intended to treat valvular regurgitation with an initial focus on the tricuspid valve. The device mimics open-heart annuloplasty without opening the chest by leaving a minimal implant around the valve annulus and is designed to avoid pacemaker leads. Company claims its independent arms, novel anchor concepts, and broad annulus-size range could expand therapy to a much larger portion of patients. There are more than 70 million people worldwide with tricuspid regurgitation and the company positions its technology to address limitations of current devices and trials. The $1.8M seed financing will support company growth and continued development of the one-size-fits-all system. ConKay anticipates a next financing round in Q2 2024 to support first-in-human testing.